Dr. Triebel on the Rationale for a Novel Immunotherapy Combination in Melanoma

Frederic Triebel, MD, PhD
Published: Tuesday, Jan 29, 2019



Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma.

An ongoing study is looking at combining PD-1 inhibition, specifically pembrolizumab (Keytruda), with antigen-presenting cells in an attempt to block 2 checkpoints concurrently. Approximately 30% of patients with a “hot tumor” microenvironment will respond to anti-PD–L1 therapy, says Triebel. By bringing together 2 checkpoint inhibitors, investigators hope to broaden the utility of immunotherapy in melanoma.

In the trial, patients were given a low dose of the soluble LAG-3 protein, eftilagimod alpha (IMP321). No significant adverse events were reported in patients who received the 1 mg dose, or those who were escalated to receive 6 mg, and subsequently, 30 mg, says Triebel. Phase II trials are also underway in frontline and second-line lung cancer as well as in head and neck cancer, he concludes.
SELECTED
LANGUAGE


Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma.

An ongoing study is looking at combining PD-1 inhibition, specifically pembrolizumab (Keytruda), with antigen-presenting cells in an attempt to block 2 checkpoints concurrently. Approximately 30% of patients with a “hot tumor” microenvironment will respond to anti-PD–L1 therapy, says Triebel. By bringing together 2 checkpoint inhibitors, investigators hope to broaden the utility of immunotherapy in melanoma.

In the trial, patients were given a low dose of the soluble LAG-3 protein, eftilagimod alpha (IMP321). No significant adverse events were reported in patients who received the 1 mg dose, or those who were escalated to receive 6 mg, and subsequently, 30 mg, says Triebel. Phase II trials are also underway in frontline and second-line lung cancer as well as in head and neck cancer, he concludes.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x